{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T03:51:59Z","timestamp":1792900319981,"version":"4.5.0"},"reference-count":37,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T00:00:00Z","timestamp":1774310400000},"content-version":"vor","delay-in-days":36,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001734","name":"Copenhagen University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001734","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-026-15743-7","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T04:50:45Z","timestamp":1771217445000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["A phase 1b open-label, dose-escalating study of safety and efficacy of disulfiram, copper and vinorelbine in advanced solid tumors"],"prefix":"10.1186","volume":"26","author":[{"given":"Rikke L\u00f8vendahl","family":"Eefsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Stenvang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Bartek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Line","family":"Tarpgaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susann","family":"Theile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nils","family":"Br\u00fcnner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte L.","family":"Nielsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,16]]},"reference":[{"issue":"7","key":"15743_CR1","doi-asserted-by":"publisher","first-page":"1876","DOI":"10.1038\/bjc.2013.534","volume":"109","author":"P Liu","year":"2013","unstructured":"Liu P, Kumar IS, Brown S, Kannappan V, Tawari PE, Tang JZ, et al. Disulfiram targets cancer stem-like cells and reverses resistance and cross-resistance in acquired paclitaxel-resistant triple-negative breast cancer cells. Br J Cancer. 2013;109(7):1876\u201385.","journal-title":"Br J Cancer"},{"issue":"17","key":"15743_CR2","doi-asserted-by":"publisher","first-page":"7471","DOI":"10.18632\/oncotarget.2166","volume":"5","author":"P Liu","year":"2014","unstructured":"Liu P, Wang Z, Brown S, Kannappan V, Tawari PE, Jiang W, et al. Liposome encapsulated Disulfiram inhibits NFkappaB pathway and targets breast cancer stem cells in vitro and in vivo. Oncotarget. 2014;5(17):7471\u201385.","journal-title":"Oncotarget"},{"key":"15743_CR3","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1186\/1479-5876-12-163","volume":"12","author":"J Zha","year":"2014","unstructured":"Zha J, Chen F, Dong H, Shi P, Yao Y, Zhang Y, et al. Disulfiram targeting lymphoid malignant cell lines via ROS-JNK activation as well as Nrf2 and NF-kB pathway Inhibition. J Transl Med. 2014;12:163.","journal-title":"J Transl Med"},{"issue":"19","key":"15743_CR4","doi-asserted-by":"publisher","first-page":"6070","DOI":"10.1158\/1078-0432.CCR-09-1035","volume":"15","author":"K Iljin","year":"2009","unstructured":"Iljin K, Ketola K, Vainio P, Halonen P, Kohonen P, Fey V, et al. High-throughput cell-based screening of 4910 known drugs and drug-like small molecules identifies Disulfiram as an inhibitor of prostate cancer cell growth. Clin Cancer Res. 2009;15(19):6070\u20138.","journal-title":"Clin Cancer Res"},{"issue":"21","key":"15743_CR5","doi-asserted-by":"publisher","first-page":"10425","DOI":"10.1158\/0008-5472.CAN-06-2126","volume":"66","author":"D Chen","year":"2006","unstructured":"Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via Inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425\u201333.","journal-title":"Cancer Res"},{"issue":"20","key":"15743_CR6","doi-asserted-by":"publisher","first-page":"5819","DOI":"10.1158\/0008-5472.CAN-13-3527","volume":"74","author":"R Safi","year":"2014","unstructured":"Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR, et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Res. 2014;74(20):5819\u201331.","journal-title":"Cancer Res"},{"issue":"7684","key":"15743_CR7","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1038\/nature25016","volume":"552","author":"Z Skrott","year":"2017","unstructured":"Skrott Z, Mistrik M, Andersen KK, Friis S, Majera D, Gursky J, et al. Alcohol-abuse drug Disulfiram targets cancer via p97 Segregase adaptor NPL4. Nature. 2017;552(7684):194\u20139.","journal-title":"Nature"},{"issue":"40","key":"15743_CR8","doi-asserted-by":"publisher","first-page":"6711","DOI":"10.1038\/s41388-019-0915-2","volume":"38","author":"Z Skrott","year":"2019","unstructured":"Skrott Z, Majera D, Gursky J, Buchtova T, Hajduch M, Mistrik M, et al. Disulfiram\u2019s anti-cancer activity reflects targeting NPL4, not Inhibition of aldehyde dehydrogenase. Oncogene. 2019;38(40):6711\u201322.","journal-title":"Oncogene"},{"issue":"5","key":"15743_CR9","doi-asserted-by":"publisher","first-page":"e2797","DOI":"10.1038\/cddis.2017.176","volume":"8","author":"B Xu","year":"2017","unstructured":"Xu B, Wang S, Li R, Chen K, He L, Deng M, et al. Disulfiram\/copper selectively eradicates AML leukemia stem cells in vitro and in vivo by simultaneous induction of ROS-JNK and Inhibition of NF-kappaB and Nrf2. Cell Death Dis. 2017;8(5):e2797.","journal-title":"Cell Death Dis"},{"key":"15743_CR10","doi-asserted-by":"crossref","unstructured":"J S. Abstract A143: repurposing Disulfiram as a potential novel treatment of drug-resistant colorectal cancer. Mol Cancer Ther. 2018;17:A143.","DOI":"10.1158\/1535-7163.TARG-17-A143"},{"issue":"4","key":"15743_CR11","doi-asserted-by":"publisher","first-page":"1010","DOI":"10.1016\/j.bbrc.2014.03.047","volume":"446","author":"L Duan","year":"2014","unstructured":"Duan L, Shen H, Zhao G, Yang R, Cai X, Zhang L, et al. Inhibitory effect of Disulfiram\/copper complex on non-small cell lung cancer cells. Biochem Biophys Res Commun. 2014;446(4):1010\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"6","key":"15743_CR12","first-page":"1069","volume":"40","author":"HJ Cho","year":"2007","unstructured":"Cho HJ, Lee TS, Park JB, Park KK, Choe JY, Sin DI, et al. Disulfiram suppresses invasive ability of osteosarcoma cells via the Inhibition of MMP-2 and MMP-9 expression. J Biochem Mol Biol. 2007;40(6):1069\u201376.","journal-title":"J Biochem Mol Biol"},{"key":"15743_CR13","doi-asserted-by":"publisher","unstructured":"MajeraD, Skrott Z, Chroma K, Merchut-Maya JM, Mistrik M, Bartek J. Targeting the NPL4 adaptor of p97\/VCP Segregase by Disulfiram as an emerging cancer vulnerability evokes replication stress and DNA damage while Silencing the ATR pathway. Cells. 2020;9(2):469 https:\/\/doi.org\/10.3390\/cells9020469.","DOI":"10.3390\/cells9020469"},{"issue":"7","key":"15743_CR14","doi-asserted-by":"publisher","first-page":"1666","DOI":"10.1038\/s41418-023-01167-4","volume":"30","author":"DC Kanellis","year":"2023","unstructured":"Kanellis DC, Zisi A, Skrott Z, Lemmens B, Espinoza JA, Kosar M, et al. Actionable cancer vulnerability due to translational arrest, p53 aggregation and ribosome biogenesis stress evoked by the Disulfiram metabolite CuET. Cell Death Differ. 2023;30(7):1666\u201378.","journal-title":"Cell Death Differ"},{"issue":"9","key":"15743_CR15","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1158\/1535-7163.1049.3.9","volume":"3","author":"SS Brar","year":"2004","unstructured":"Brar SS, Grigg C, Wilson KS, Holder WD Jr., Dreau D, Austin C, et al. Disulfiram inhibits activating transcription factor\/cyclic AMP-responsive element binding protein and human melanoma growth in a metal-dependent manner in vitro, in mice and in a patient with metastatic disease. Mol Cancer Ther. 2004;3(9):1049\u201360.","journal-title":"Mol Cancer Ther"},{"issue":"11","key":"15743_CR16","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1093\/jnci\/92.11.898","volume":"92","author":"TW Loo","year":"2000","unstructured":"Loo TW, Clarke DM. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J Natl Cancer Inst. 2000;92(11):898\u2013902.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"15743_CR17","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2174\/1574892814666190514104035","volume":"14","author":"E Ekinci","year":"2019","unstructured":"Ekinci E, Rohondia S, Khan R, Dou QP. Repurposing Disulfiram as an anti-Cancer agent: updated review on literature and patents. Recent Pat Anticancer Drug Discov. 2019;14(2):113\u201332.","journal-title":"Recent Pat Anticancer Drug Discov"},{"issue":"1","key":"15743_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/BF01877380","volume":"6","author":"P Dufour","year":"1993","unstructured":"Dufour P, Lang JM, Giron C, Duclos B, Haehnel P, Jaeck D, et al. Sodium Dithiocarb as adjuvant immunotherapy for high risk breast cancer: a randomized study. Biotherapy. 1993;6(1):9\u201312.","journal-title":"Biotherapy"},{"issue":"1","key":"15743_CR19","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.canlet.2009.09.002","volume":"290","author":"X Guo","year":"2010","unstructured":"Guo X, Xu B, Pandey S, Goessl E, Brown J, Armesilla AL, et al. Disulfiram\/copper complex inhibiting NFkappaB activity and potentiating cytotoxic effect of gemcitabine on colon and breast cancer cell lines. Cancer Lett. 2010;290(1):104\u201313.","journal-title":"Cancer Lett"},{"issue":"4","key":"15743_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1016\/j.bbrc.2019.03.192","volume":"513","author":"SY You","year":"2019","unstructured":"You SY, Rui W, Chen ST, Chen HC, Liu XW, Huang J, et al. Process of Immunogenic cell death caused by Disulfiram as the anti-colorectal cancer candidate. Biochem Biophys Res Commun. 2019;513(4):891\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"16","key":"15743_CR21","doi-asserted-by":"publisher","first-page":"e110636","DOI":"10.15252\/embj.2022110636","volume":"41","author":"Q Wang","year":"2022","unstructured":"Wang Q, Zhu T, Miao N, Qu Y, Wang Z, Chao Y, et al. Disulfiram bolsters T-cell anti-tumor immunity through direct activation of LCK-mediated TCR signaling. EMBO J. 2022;41(16):e110636.","journal-title":"EMBO J"},{"key":"15743_CR22","doi-asserted-by":"crossref","unstructured":"Zirjacks L, Stransky N, Klumpp L, Prause L, Eckert F, Zips D et al. Repurposing Disulfiram for targeting of glioblastoma stem cells: an in vitro study. Biomolecules. 2021;11(11).","DOI":"10.3390\/biom11111561"},{"key":"15743_CR23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.3390\/cancers14194715","volume":"14","author":"X Gao","year":"2022","unstructured":"Gao X, Huang H, Pan C, Mei Z, Yin S, Zhou L, et al. Disulfiram\/Copper induces Immunogenic cell death and enhances CD47 Blockade in hepatocellular carcinoma. Cancers (Basel). 2022;14:19.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"15743_CR24","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1016\/j.molonc.2015.02.007","volume":"9","author":"JL Allensworth","year":"2015","unstructured":"Allensworth JL, Evans MK, Bertucci F, Aldrich AJ, Festa RA, Finetti P, et al. Disulfiram (DSF) acts as a copper ionophore to induce copper-dependent oxidative stress and mediate anti-tumor efficacy in inflammatory breast cancer. Mol Oncol. 2015;9(6):1155\u201368.","journal-title":"Mol Oncol"},{"issue":"1","key":"15743_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/s13643-021-01858-4","volume":"11","author":"L Wang","year":"2022","unstructured":"Wang L, Yu Y, Zhou C, Wan R, Li Y. Anticancer effects of disulfiram: a systematic review of in vitro, animal, and human studies. Syst Rev. 2022;11(1):109.","journal-title":"Syst Rev"},{"issue":"1","key":"15743_CR26","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s11060-018-2775-y","volume":"138","author":"J Huang","year":"2018","unstructured":"Huang J, Campian JL, Gujar AD, Tsien C, Ansstas G, Tran DD, et al. Final results of a phase I dose-escalation, dose-expansion study of adding Disulfiram with or without copper to adjuvant Temozolomide for newly diagnosed glioblastoma. J Neurooncol. 2018;138(1):105\u201311.","journal-title":"J Neurooncol"},{"issue":"3","key":"15743_CR27","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s11060-019-03125-y","volume":"142","author":"J Huang","year":"2019","unstructured":"Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J, et al. A multicenter phase II study of Temozolomide plus Disulfiram and copper for recurrent Temozolomide-resistant glioblastoma. J Neurooncol. 2019;142(3):537\u201344.","journal-title":"J Neurooncol"},{"issue":"3","key":"15743_CR28","doi-asserted-by":"publisher","first-page":"e234149","DOI":"10.1001\/jamanetworkopen.2023.4149","volume":"6","author":"K Werlenius","year":"2023","unstructured":"Werlenius K, Kinhult S, Solheim TS, Magelssen H, Lofgren D, Mudaisi M, et al. Effect of Disulfiram and copper plus chemotherapy vs chemotherapy alone on survival in patients with recurrent glioblastoma: A randomized clinical trial. JAMA Netw Open. 2023;6(3):e234149.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"15743_CR29","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1634\/theoncologist.2014-0424","volume":"20","author":"H Nechushtan","year":"2015","unstructured":"Nechushtan H, Hamamreh Y, Nidal S, Gotfried M, Baron A, Shalev YI, et al. A phase IIb trial assessing the addition of Disulfiram to chemotherapy for the treatment of metastatic non-small cell lung cancer. Oncologist. 2015;20(4):366\u20137.","journal-title":"Oncologist"},{"issue":"5","key":"15743_CR30","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1007\/s10637-022-01271-1","volume":"40","author":"M Mego","year":"2022","unstructured":"Mego M, Svetlovska D, Angelis VD, Kalavska K, Lesko P, Makovnik M, et al. Phase II study of Disulfiram and cisplatin in refractory germ cell Tumors. The GCT-SK-006 phase II trial. Invest New Drugs. 2022;40(5):1080\u20136.","journal-title":"Invest New Drugs"},{"issue":"7","key":"15743_CR31","doi-asserted-by":"publisher","first-page":"858","DOI":"10.1002\/pros.24329","volume":"82","author":"T Zhang","year":"2022","unstructured":"Zhang T, Kephart J, Bronson E, Anand M, Daly C, Spasojevic I, et al. Prospective clinical trial of Disulfiram plus copper in men with metastatic castration-resistant prostate cancer. Prostate. 2022;82(7):858\u201366.","journal-title":"Prostate"},{"issue":"1","key":"15743_CR32","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1186\/s12885-021-08242-4","volume":"21","author":"KC Kelley","year":"2021","unstructured":"Kelley KC, Grossman KF, Brittain-Blankenship M, Thorne KM, Akerley WL, Terrazas MC, et al. A phase 1 dose-escalation study of Disulfiram and copper gluconate in patients with advanced solid tumors involving the liver using S-glutathionylation as a biomarker. BMC Cancer. 2021;21(1):510.","journal-title":"BMC Cancer"},{"issue":"3","key":"15743_CR33","doi-asserted-by":"publisher","first-page":"738","DOI":"10.1016\/j.ijrobp.2024.05.009","volume":"120","author":"J Huang","year":"2024","unstructured":"Huang J, Campian JL, DeWees TA, Skrott Z, Mistrik M, Johanns TM, et al. A phase 1\/2 study of Disulfiram and copper with concurrent radiation therapy and Temozolomide for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2024;120(3):738\u201349.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"15743_CR34","doi-asserted-by":"publisher","first-page":"200","DOI":"10.2165\/00002512-199405030-00006","volume":"5","author":"KL Goa","year":"1994","unstructured":"Goa KL, Faulds D, Vinorelbine. A review of its Pharmacological properties and clinical use in cancer chemotherapy. Drugs Aging. 1994;5(3):200\u201334.","journal-title":"Drugs Aging"},{"issue":"10","key":"15743_CR35","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/jnnp.55.10.925","volume":"55","author":"D Laplane","year":"1992","unstructured":"Laplane D, Attal N, Sauron B, de Billy A, Dubois B. Lesions of basal ganglia due to Disulfiram neurotoxicity. J Neurol Neurosurg Psychiatry. 1992;55(10):925\u20139.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"15743_CR36","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13256-016-0865-z","volume":"10","author":"AT Tran","year":"2016","unstructured":"Tran AT, Rison RA, Beydoun SR. Disulfiram neuropathy: two case reports. J Med Case Rep. 2016;10:72.","journal-title":"J Med Case Rep"},{"issue":"2","key":"15743_CR37","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/0303-8467(84)90070-2","volume":"86","author":"J van Rossum","year":"1984","unstructured":"van Rossum J, Roos RA, Bots GT. Disulfiram polyneuropathy. Clin Neurol Neurosurg. 1984;86(2):81\u20137.","journal-title":"Clin Neurol Neurosurg"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15743-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15743-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T11:53:11Z","timestamp":1774353191000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15743-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,16]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15743"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15743-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,16]]},"assertion":[{"value":"15 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The trial was registered with EudraCT 2019-001972-12. It was approved by the Ethical Committee, Capital Region of Denmark, approval number: H-19039582. Data registry number, Capital Region of Denmark P-2019-609. The study is in compliance with the Helsinki Declaration (\n                      \n                      ). An informed signed consent was completed for all patients screened and enrolled in this trial.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"385"}}